Teijin-developed Novel Drug for Chronic Management of Hyperuricemia 'TMX-67 (febuxostat)' Approved in Japan

25-Jan-2011 - Japan

Teijin Pharma Limited announced that Japan's Ministry of Health, Labour and Welfare approved TMX-67 (febuxostat), Teijin Pharma's novel drug for treating hyperuricemia, on January 21. Teijin Pharma will market the product as tablets in 10mg, 20mg, and 40mg strengths in Japan under the brand name Feburic(R) beginning this spring.

TMX-67, a highly potent oral drug taken once daily, is the world's first non-purine selective inhibitor of xanthine oxidase. It has a novel chemical structure completely different from that of allopurinol, which has been used for over 40 years as the standard treatment for hyperuricemia. TMX-67 is the first drug indicated for treatment of hyperuricemia with or without symptoms (e.g. gout, hypertension, etc.) in Japan. It effectively lowers the level of uric acid in the blood of hyperuricemic patients to the recommended level of less than 6.0mg/dL, and is well tolerated by patients suffering from mild to moderate renal impairment without any dose adjustment.

Other news from the department research and development

Most read news

More news from our other portals

Fighting cancer: latest developments and advances